The Centers for Medicare and Medicaid Services recently announced—without explanation—that it would not proceed with a ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

By Puyaan Singh (Reuters) - The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a ...

The Centers for Medicare & Medicaid Services on Friday rejected a Biden administration proposal to expand Medicare coverage of weight-loss drugs such as Eli Lilly's Zepbound and Novo Nordisk's ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, the Centers for Medicare and Medicaid Services said in a filing published ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Kennedy Jr., has been an outspoken opponent of the injectable drugs, which have exploded in popularity due to the potentially ...

In a New York Times column this week, the Pennsylvania Democrat shared his experience taking Mounjaro while advocating for ...

Some of the more than a dozen states that cover the high cost of GLP-1 drugs like Wegovy, Ozempic and Zepbound through ...

Popular weight loss drugs may do more than curb appetite — they may also help reduce the risk of dementia, according to new research.